These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37376207)

  • 1. Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide Antibiotics.
    Parmar KR; Lukka PB; Wagh S; Temrikar ZH; Liu J; Lee RE; Braunstein M; Hickey AJ; Robertson GT; Gonzalez-Juarrero M; Edginton A; Meibohm B
    Pharmaceutics; 2023 Jun; 15(6):. PubMed ID: 37376207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Inhalational Spectinamide-1599 Therapy against Tuberculosis.
    Gonzalez-Juarrero M; Lukka PB; Wagh S; Walz A; Arab J; Pearce C; Ali Z; Ryman JT; Parmar K; Temrikar Z; Munoz-Gutierrez J; Robertson GT; Liu J; Lenaerts AJ; Daley C; Lee RE; Braunstein M; Hickey AJ; Meibohm B
    ACS Infect Dis; 2021 Oct; 7(10):2850-2863. PubMed ID: 34546724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.
    Wagh S; Rathi C; Lukka PB; Parmar K; Temrikar Z; Liu J; Scherman MS; Lee RE; Robertson GT; Lenaerts AJ; Meibohm B
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0174420. PubMed ID: 34424046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic time-kill curve characterization of spectinamide antibiotics 1445 and 1599 for the treatment of tuberculosis.
    Vaddady PK; Trivedi A; Rathi C; Madhura DB; Liu J; Lee RE; Meibohm B
    Eur J Pharm Sci; 2019 Jan; 127():233-239. PubMed ID: 30419293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
    Hu ZY; Lu J; Zhao Y
    Br J Pharmacol; 2014 Jun; 171(11):2778-89. PubMed ID: 24471734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.
    Alasmari F; Alasmari MS; Muwainea HM; Alomar HA; Alasmari AF; Alsanea S; Alshamsan A; Rasool MF; Alqahtani F
    Front Pharmacol; 2023; 14():1200828. PubMed ID: 37547336
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes.
    Temrikar ZH; Kodidela S; Kumar S; Liu J; Robertson GT; Lee RE; Hickey AJ; Gonzalez-Juarrero M; Meibohm B
    Tuberculosis (Edinb); 2023 May; 140():102342. PubMed ID: 37120915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of spectinamide 1599 after subcutaneous and intrapulmonary aerosol administration in mice.
    Rathi C; Lukka PB; Wagh S; Lee RE; Lenaerts AJ; Braunstein M; Hickey A; Gonzalez-Juarrero M; Meibohm B
    Tuberculosis (Edinb); 2019 Jan; 114():119-122. PubMed ID: 30711150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically-based pharmacokinetic modeling.
    Lee JB; Zhou S; Chiang M; Zang X; Kim TH; Kagan L
    Biopharm Drug Dispos; 2020 Apr; 41(4-5):192-205. PubMed ID: 32342986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human.
    Chen Y; Zhao K; Liu F; Xie Q; Zhong Z; Miao M; Liu X; Liu L
    Front Pharmacol; 2016; 7():488. PubMed ID: 28018224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens.
    Adiwidjaja J; Gross AS; Boddy AV; McLachlan AJ
    Br J Clin Pharmacol; 2022 Feb; 88(4):1735-1750. PubMed ID: 34535920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis.
    Reali F; Fochesato A; Kaddi C; Visintainer R; Watson S; Levi M; Dartois V; Azer K; Marchetti L
    Front Pharmacol; 2023; 14():1272091. PubMed ID: 38239195
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment and Confirmation of Species Difference in Nonlinear Pharmacokinetics of Atipamezole with Physiologically Based Pharmacokinetic Modeling.
    Li Z; Gao Y; Yang C; Xiang Y; Zhang W; Zhang T; Su R; Lu C; Zhuang X
    Drug Metab Dispos; 2020 Jan; 48(1):41-51. PubMed ID: 31699808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection.
    Muliaditan M; Teutonico D; Ortega-Muro F; Ferrer S; Della Pasqua O
    Eur J Pharm Sci; 2022 Jun; 173():106163. PubMed ID: 35248733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PBPK Modeling as an Alternative Method of Interspecies Extrapolation that Reduces the Use of Animals: A Systematic Review.
    Lancheros Porras KD; Alves IA; Novoa DMA
    Curr Med Chem; 2024; 31(1):102-126. PubMed ID: 37031391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in Animals.
    Shimizu H; Yoshida K; Nakada T; Kojima K; Ogasawara A; Nakamaru Y; Yamazaki H
    Drug Metab Dispos; 2019 Feb; 47(2):114-123. PubMed ID: 30420404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertin.
    Parrott N; Hainzl D; Alberati D; Hofmann C; Robson R; Boutouyrie B; Martin-Facklam M
    Clin Pharmacokinet; 2013 Aug; 52(8):673-83. PubMed ID: 23591780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
    Ahmad A; Pepin X; Aarons L; Wang Y; Darwich AS; Wood JM; Tannergren C; Karlsson E; Patterson C; Thörn H; Ruston L; Mattinson A; Carlert S; Berg S; Murphy D; Engman H; Laru J; Barker R; Flanagan T; Abrahamsson B; Budhdeo S; Franek F; Moir A; Hanisch G; Pathak SM; Turner D; Jamei M; Brown J; Good D; Vaidhyanathan S; Jackson C; Nicolas O; Beilles S; Nguefack JF; Louit G; Henrion L; Ollier C; Boulu L; Xu C; Heimbach T; Ren X; Lin W; Nguyen-Trung AT; Zhang J; He H; Wu F; Bolger MB; Mullin JM; van Osdol B; Szeto K; Korjamo T; Pappinen S; Tuunainen J; Zhu W; Xia B; Daublain P; Wong S; Varma MVS; Modi S; Schäfer KJ; Schmid K; Lloyd R; Patel A; Tistaert C; Bevernage J; Nguyen MA; Lindley D; Carr R; Rostami-Hodjegan A
    Eur J Pharm Biopharm; 2020 Nov; 156():50-63. PubMed ID: 32805361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.